Publications

If you have OHDSI-related publications you’d like added to this list, please email Maura Beaton at beaton@ohdsi.org with a list of publications, written out as you would like them to appear online.

Featured Publications

George Hripcsak, Jon D Duke, Nigam H Shah, Christian G Reich, Vojtech Huser, Martijn J Schuemie, Marc A Suchard, Rae Woong Park, Ian Chi Kei Wong, Peter R Rijnbeek, Johan van der Lei, Nicole Pratt, G Niklas Norén, Yu-Chuan Li, Paul E Stang, David Madigan, and Patrick B Ryan. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015; 216: 574–578.

OHDSI Publications

Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich CG, Weaver J, Schuemie MJ, Ryan PB, Callahan A, Shah NH. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Network Open 2018, 1(4), pp.e181755-e181755.

Banda JM, Halpern Y, Sontag D, Shah NH. Electronic phenotyping with APHRODITE and the Observational Health Sciences and Informatics (OHDSI) data network. AMIA Jt Summits Transl Sci Proc. 2017, 48-57. Published 2017 Jul 26

You, Seng Chan, Min Ho An, Dukyong Yoon, Ga-Young Ban, Pil-Sung Yang, Hee Tae Yu, Rae Woong Park, and Boyoung Joung. “Rate Control and Clinical Outcomes in Patients with Atrial Fibrillation and Obstructive Lung Disease.” Heart Rhythm (July 3, 2018). https://doi.org/10.1016/j.hrthm.2018.06.044.

Boyce RD, Handler SM, Karp JF, Perera S, Reynolds CF 3rd. Preparing Nursing. Home Data from Multiple Sites for Clinical Research – A Case Study Using Observational Health Data Sciences and Informatics. EGEMS (Wash DC). 2016 Oct 26;4(1):1252. PubMed PMID: 27891528. DOI: http://dx.doi.org/10.13063/2327-9214.1252.

Huser, Vojtech; DeFalco, Frank J.; Schuemie, Martijn; Ryan, Patrick B.; Shang, Ning; Velez, Mark; Park, Rae Woong; Boyce, Richard D.; Duke, Jon; Khare, Ritu; Utidjian, Levon; and Bailey, Charles (2016) “Multisite Evaluation of a Data Quality Tool for Patient-Level Clinical Datasets,” eGEMs (Generating Evidence & Methods to improve patient outcomes): Vol. 4: Iss. 1, Article 24. DOI: http://dx.doi.org/10.13063/2327-9214.1239.

Samwald M, Xu H, Blagec K, Empey PE, Malone DC, Ahmed SM, Ryan P, Hofer S, Boyce RD. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. PLoS One. 2016 Oct 20;11(10):e0164972. doi: 10.1371/journal.pone.0164972. PubMed PMID: 27764192.

E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464.

Agarwal V, Podchiyska T, Banda JM, Goel V, Leung TI, Minty EP, Sweeney TE, Gyang E, Shah NH. Learning statistical models of phenotypes using noisy labeled training data. J Am Med Inform Assoc. 2016 May 12. pii: ocw028. doi: 10.1093/jamia/ocw028.

Yoni Halpern, Steven Horng, Youngduck Choi, David Sontag. Electronic medical record phenotyping using the anchor and learn framework. DOI: http://dx.doi.org/10.1093/jamia/ocw011 ocw011 First published online: 23 April 2016.

Weinstein RB, Schuemie MJ, Ryan PB, Stang PE. Seasonality in acute liver injury? Findings in two health care claims databases. Drug Healthc Patient Saf. 2016 Mar 31;8:39-48. doi: 10.2147/DHPS.S95399. eCollection 2016.

Yoon D, Schuemie MJ, Kim JH, Kim DK, Park MY, Ahn EK, Jung EY, Park DK, Cho SY, Shin D, Hwang Y, Park RW. A normalization method for combination of laboratory test results from different electronic healthcare databases in a distributed research network. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):307-16. doi: 10.1002/pds.3893. Epub 2015 Nov 3.

Hripcsak G, Mirhaji P, Low AF, Malin BA. Preserving temporal relations in clinical data while maintaining privacy. J Am Med Inform Assoc. 2016 Mar 24. pii: ocw001. doi: 10.1093/jamia/ocw001.

Boland MR, Jacunski A, Lorberbaum T, Romano JD, Moskovitch R, Tatonetti NP. Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms. Wiley Interdiscip Rev Syst Biol Med. 2016 Mar;8(2):104-22. doi: 10.1002/wsbm.1323. Epub 2015 Nov 12.

Juan M. Banda, Lee Evans, Rami S. Vanguri, Nicholas P. Tatonetti, Patrick B. Ryan & Nigam H. Shah. A curated and standardized adverse drug event resource to accelerate drug safety research. Scientific Data, DOI: 10.1038/sdata.2016.26

Gini R, Schuemie M, Brown J, Ryan P, Vacchi E, Coppola M, Cazzola W, Coloma P, Berni R, Diallo G, Oliveira JL, Avillach P, Trifirò G, Rijnbeek P, Bellentani M, van Der Lei J, Klazinga N, Sturkenboom M. Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies. EGEMS (Wash DC). 2016 Feb 8;4(1):1189. doi: 10.13063/2327-9214.1189. eCollection 2016.

Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research. Healthc Inform Res. 2016 Jan;22(1):54-8. doi: 10.4258/hir.2016.22.1.54. Epub 2016 Jan 31.

Banda JM, Callahan A, Winnenburg R, Strasberg HR, Cami A, Reis BY, Vilar S, Hripcsak G, Dumontier M, Shah NH. Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records. Drug Saf. 2016 Jan;39(1):45-57. doi: 10.1007/s40264-015-0352-2.

Pacurariu AC, Straus SM, Trifirò G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. Drug Saf. 2015 Dec;38(12):1201-10. doi: 10.1007/s40264-015-0341-5.

Abedtash H, Duke JD. An Interactive User Interface for Drug Labeling to Improve Readability and Decision-Making. AMIA Annu Symp Proc. 2015 Nov 5;2015:278-86. eCollection 2015.

Li Y, Ryan PB, Wei Y, Friedman C. A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. Drug Saf. 2015 Oct;38(10):895-908. doi: 10.1007/s40264-015-0314-8.

de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Pedersen L, Stricker BH, van der Lei J, Sturkenboom MC; EU-ADR consortium. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. Br J Clin Pharmacol. 2015 Aug;80(2):304-14. doi: 10.1111/bcp.12610. Epub 2015 May 20.

Hripcsak G, Albers DJ, Perotte A. Parameterizing time in electronic health record studies. J Am Med Inform Assoc. 2015 Jul;22(4):794-804. doi: 10.1093/jamia/ocu051. Epub 2015 Feb 26.

Vilar S, Lorberbaum T, Hripcsak G, Tatonetti NP. Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling. PLoS One. 2015 Jun 12;10(6):e0129974. doi: 10.1371/journal.pone.0129974. eCollection 2015.

Boland MR, Shahn Z, Madigan D, Hripcsak G, Tatonetti NP. Birth month affects lifetime disease risk: a phenome-wide method. J Am Med Inform Assoc. 2015 Sep;22(5):1042-53. doi: 10.1093/jamia/ocv046. Epub 2015 Jun 2.

Dukyong Yoon, Martijn J. Schuemie, Ju Han Kim, Dong Ki Kim, Man Young Park, Eun Kyoung Ahn, Eun-Young Jung, Dong Kyun Park, Soo Yeon Cho, Dahye Shin, Yeonsoo Hwang, Rae Woong Park. A normalization method for combination of laboratory test results from different electronic healthcare databases in a distributed research network. Pharmacoepidemiology and Drug Safety.

Boyce RD, Ryan PB, Noren GN, et al. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Saf. 2014 Jul 2;2:2.

Boland MR, Tatonetti NP, Hripcsak G. Development and validation of a classification approach for extracting severity automatically from electronic health records. J Biomed Semantics. 2015 Apr 6;6:14. doi: 10.1186/s13326-015-0010-8. eCollection 2015.

Kahn MG, Brown JS, Chun AT, Davidson BN, Meeker D, Ryan PB, Schilling LM, Weiskopf NG, Williams AE, Zozus MN. Transparent reporting of data quality in distributed data networks. EGEMS (Wash DC). 2015 Mar 23;3(1):1052. doi: 10.13063/2327-9214.1052. eCollection 2015.

Voss EA, Ma Q, Ryan PB. The impact of standardizing the definition of visits on the consistency of multi-database observational health research. BMC Med Res Methodol. 2015 Mar 8;15:13. doi: 10.1186/s12874-015-0001-6.

Voss E, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco F, Londhe A, Zhu V, Ryan P. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association Feb 2015.

Weng C, Li Y, Ryan P, et al. A Distribution-based Method for Assessing The Differences between Clinical Trial Target Populations and Patient Populations in Electronic Health Records. Appl Clin Inform. 2014 May 7;5(2):463-79. doi: 10.4338/ACI-2013-12-RA-0105. eCollection 2014.

Boland MR, Tatonetti NP, Hripcsak G. CAESAR: a Classification Approach for Extracting Severity Automatically from Electronic Health Records. Intelligent Systems for Molecular Biology Phenotype Day. 2014; Boston, MA.

Vilar S, Ryan PB, Madigan D, Stang PE, Schuemie MJ, Friedman C, Tatonetti NP, Hripcsak G. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol. 2014 Sep 24;3:e137. doi: 10.1038/psp.2014.35.

Ohno-Machado L, Agha Z, Bell DS, Dahm L, Day ME, Doctor JN, Gabriel D, Kahlon MK, Kim KK, Hogarth M, Matheny ME, Meeker D, Nebeker JR; pSCANNER team. pSCANNER: patient-centered Scalable National Network for Effectiveness Research. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):621-6. doi: 10.1136/amiajnl-2014-002751. Epub 2014 Apr 29.

Kaushal R, Hripcsak G, Ascheim DD, Bloom T, Campion TR Jr, Caplan AL, Currie BP, Check T, Deland EL, Gourevitch MN, Hart R, Horowitz CR, Kastenbaum I, Levin AA, Low AF, Meissner P, Mirhaji P, Pincus HA, Scaglione C, Shelley D, Tobin JN; NYC-CDRN. Changing the research landscape: the New York City Clinical Data Research Network. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):587-90. doi: 10.1136/amiajnl-2014-002764. Epub 2014 May 12.

Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG. PEDSnet: a National Pediatric Learning Health System. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):602-6. doi: 10.1136/amiajnl-2014-002743. Epub 2014 May 12.

OMOP Publications

Schuemie MJ, Trifiro G, Coloma PM, Ryan PB, Madigan D. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series. Stat Methods Med Res. 2014 Mar 31;31:31.

Madigan D, Stang PE, Berlin JA, et al. A Systematic Statistical Approach to Evaluating Evidence from Observational Studies. Annual Review of Statistics and Its Application. 2014;1(1):11-39.

Mittal S, Madigan D, Burd RS, Suchard MA. High-dimensional, massive sample-size Cox proportional hazards regression for survival analysis. Biostatistics. 2014 Apr;15(2):207-21. doi: 10.1093/biostatistics/kxt043. Epub 2013 Oct 4.

Schuemie MJ, Ryan PB, Suchard MA, Shahn Z, Madigan D. Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics. 2014 Jan;15(1):36-9; discussion 9-45. doi: 10.1093/biostatistics/kxt037. Epub 2013 Sep 25.

Paul Stang PR, Abraham G. Hartzema, David Madigan, J Marc Overhage, Emily Welebob, Christian G. Reich, Thomas Scarnecchia. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. In: Elizabeth B. Andrews NM, editor. Mann’s Pharmacovigilance. Third ed: Wiley-Blackwell; 2014. p. 866.

Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014 Jan 30;33(2):209-18. doi: 10.1002/sim.5925. Epub 2013 Jul 30.

Hansen RA, Gray MD, Fox BI, et al. Expert panel assessment of acute liver injury identification in observational data. Res Social Adm Pharm. 2014 Jan-Feb;10(1):156-67. doi: 10.1016/j.sapharm.2013.04.012. Epub Jun 7.

Schuemie MJ, Madigan D, Ryan PB. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S133-42. doi: 10.1007/s40264-013-0107-x.

Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S73-82. doi: 10.1007/s40264-013-0105-z.

Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013 Oct;14(10):1227-41. doi: 10.016/j.jpain.2013.05.010. Epub Jul 10.

Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-wide association studies. CPT Pharmacometrics Syst Pharmacol. 2013 Sep 18;2:e76.(doi):10.1038/psp.2013.52.

Reich CG, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S195-204. doi: 10.1007/s40264-013-0112-0.

Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf. 2013 Oct;36(Suppl 1):S181-93. doi: 10.1007/s40264-013-0111-1.

Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013 Oct;36(Suppl 1):S171-80. doi: 10.1007/s40264-013-0110-2.

Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36(Suppl 1):S143-58. doi: 10.1007/s40264-013-0108-9.

DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013 Oct;36(Suppl 1):S123-32. doi: 10.1007/s40264-013-0106-y.

Noren GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S107-21. doi: 10.1007/s40264-013-0095-x.

Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S95-106. doi: 10.1007/s40264-013-0101-3.

Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S83-93. doi: 10.1007/s40264-013-0100-4.

Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 Oct;36(Suppl 1):S59-72. doi: 10.1007/s40264-013-0099-6.

Hartzema AG, Reich CG, Ryan PB, et al. Managing data quality for a drug safety surveillance system. Drug Saf. 2013 Oct;36(Suppl 1):S49-58. doi: 10.1007/s40264-013-0098-7.

Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 Oct;36(Suppl 1):S33-47. doi: 10.1007/s40264-013-0097-8.

Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf. 2013 Oct;36(Suppl 1):S15-25. doi: 10.1007/s40264-013-0103-1.

Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf. 2013 Oct;36(Suppl 1):S5-14. doi: 0.1007/s40264-013-0102-2.

Evans SJ. Moving along the yellow brick (card) road? Drug Saf. 2013 Oct;36(Suppl 1):S3-4. doi: 10.1007/s40264-013-0096-9.

Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013 Dec;69(4):893-902. doi: 10.1111/biom.12078. Epub 2013 Oct 11.

Katz AJ, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf. 2013 Aug;36(8):651-61. doi: 10.1007/s40264-013-0060-8.

Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645-51. doi: 10.1093/aje/kwt010. Epub 2013 May 5.

Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Response to comment on ’empirical assessment of methods for risk identification in healthcare data’. Stat Med. 2013 Mar 15;32(6):1075-7. doi: 10.02/sim.5725.

Defalco FJ, Ryan PB, Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol. 2013 Mar;13(1):58-67. Epub 2012 Oct 27.

Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Zeng P. How well do various health outcome definitions identify appropriate cases in observational studies? Drug Saf. 2013 Oct;36(Suppl 1):S27-32. doi: 10.1007/s40264-013-0104-0.

Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013 Oct;36(Suppl 1):S159-69. doi: 10.1007/s40264-013-0109-8.

Fox BI, Hollingsworth JC, Gray MD, Hollingsworth ML, Gao J, Hansen RA. Developing an expert panel process to refine health outcome definitions in observational data. J Biomed Inform. 2013 Oct;46(5):795-804. doi: 10.1016/j.jbi.2013.05.006. Epub Jun 13.

Ryan P, Suchard MA, Schuemie M, Madigan D. Learning From Epidemiology: Interpreting Observational Database Studies for the Effects of Medical Products. Statistics in Biopharmaceutical Research. 2013;5(3).

Madigan D, Ryan PB, Schuemie M. Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. Therapeutic Advances in Drug Safety. 2013 April 1, 2013;4(2):53-62.

Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. ACM Trans Model Comput Simul. 2013;23(1):1-17.

Ryan P. Statistical challenges in systematic evidence generation through analysis of observational healthcare data networks. Statistical Methods in Medical Research. 2013;22(1):3-6.

Overhage JM, Overhage LM. Sensible use of observational clinical data. Statistical Methods in Medical Research. 2013;22(1):7-13.

Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec 30;31(30):4401-15. doi: 10.1002/sim.5620. Epub 2012 Sep 27.

Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub Jun 7.

Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan;21(Suppl 1):32-40. doi: 10.1002/pds.2316.

Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28.

Page D, Costa VS, Natarajan S, Barnard A, Peissig P, Caldwell M. Identifying Adverse Drug Events by Relational Learning. Proc Conf AAAI Artif Intell. 2012 Jul;2012:790-3.

Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012 Jun;91(6):1010-21. doi: 10.38/clpt.2012.50.

Ryan P. Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. In: Krause A, OConnell, Michael editor. A Picture is Worth a Thousand Tables: Springer; 2012. p. 429.

Stang PE, Ryan PB, Dusetzina SB, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine. 2012 2//;3(1):e37-e44.

Murray RE, Ryan PB, Reisinger SJ. Design and validation of a data simulation model for longitudinal healthcare data. AMIA Annu Symp Proc. 2011;2011:1176-85. Epub 2011 Oct 22.

Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):292-9. doi: 10.1002/pds.2051. Epub 10 Oct 13.

Madigan D, Ryan P. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology. 2011 Sep;22(5):629-31. doi: 10.1097/EDE.0b013e318228ca1d.

Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013 Feb;22(1):39-56. doi: 10.1177/0962280211403602. Epub 2011 Aug 30.

Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.

Reisinger SJ, Ryan PB, O’Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc. 2010 Nov-Dec;17(6):652-62. doi: 10.1136/jamia.2009.002477.

Ryan P, Welebob E, Hartzema A, Stang P, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs. Pharm Med. 2010 2010/08/01;24(4):231-8.